NASDAQ: PLSMPulsenmore Ltd Stock
$4.03-0.02 (-0.49%)
Updated Jun 12, 2026
PLSM Price
$4.03
Fair Value Price
N/A
Market Cap
$26.17M
52 Week Low
$3.00
52 Week High
$10.28
P/E
-5.11x
P/B
0.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$12.83M
Earnings
-$4.97M
Gross Margin
84.2%
Operating Margin
-48.82%
Profit Margin
-39.6%
Debt to Equity
0.23
Operating Cash Flow
-$10M
Beta
0.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLSM Overview
Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLSM's potential to beat the market
- PLSM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PLSM
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.51 | A | |
| $37.14 | A | |
| $26.31 | A |
Be the first to know about important PLSM news, forecast changes, insider trades & much more!
PLSM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLSM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PLSM is good value based on its book value relative to its share price (0.98x), compared to the US Medical Devices industry average (2.98x)
P/B vs Industry Valuation
PLSM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PLSM due diligence checks available for Premium users.
Valuation
PLSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.11x
Industry
20.73x
Market
14.15x
PLSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
2.98x
PLSM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLSM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PLSM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PLSM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.9M
Liabilities
$5.9M
Debt to equity
0.23
PLSM's short-term assets ($26.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLSM's short-term assets ($26.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PLSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLSM vs Medical Device Stocks
Pulsenmore Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.